HR0136 103RD GENERAL ASSEMBLY

HR0136 LRB103 31149 ECR 57895 r

HOUSE RESOLUTION

WHEREAS, Breast cancer is among the most commonly diagnosed types of cancer and the second leading cause of cancer death among women in the United States; and

WHEREAS, Approximately 297,790 women will be diagnosed with breast cancer, and more than 43,000 will die with this malignancy in 2023; and

WHEREAS, Triple-Negative Breast Cancer (TNBC) is one of many forms of breast cancer and accounts for approximately 15 to 20% of all diagnosed invasive breast cancer cases in the United States; and

WHEREAS, In 2019, more than 53,700 new breast cancer cases in the United States were diagnosed as TNBC, with higher prevalence among younger women, Black and Hispanic women, women with type 2 diabetes or carrying excess weight in the abdomen area, and those with BRCA1 mutations; and

WHEREAS, Due to its aggressive behavior, TNBC grows quickly, is more likely to have spread at the time it is found, and is more likely to come back after treatment than other types of breast cancer; and

WHEREAS, People diagnosed with metastatic TNBC have a less than 30% chance of surviving past five years; and

WHEREAS, TNBC cells do not contain, or are "negative for", three key receptors that medicines typically target in other types of breast cancer; therefore, limited treatment options that can be used to treat the cancer; and

WHEREAS, Patients with an early diagnosis can often be treated with chemotherapy, radiation, and surgery; however, the limited therapies available, which specifically address the management of TNBC, have made treating this disease a challenge for clinicians; and

WHEREAS, Recent innovation in targeted therapies have fueled advances in the fight against TNBC; and

WHEREAS, Studies have shown that TNBC disease-specific mortality rates are often higher if patients have Medicaid or Medicare or come from a lower socioeconomic status; compared with non-Hispanic white women, Black women are 48% less likely to receive guideline adherent care and have an approximate two-fold higher mortality incidence, resulting in a disproportionately higher risk of death from TNBC; and

WHEREAS, Advances in breast cancer screening and treatment over the last few decades have reduced the overall breast cancer mortality rate, yet the disproportionate impact of TNBC on racial and ethnic minority communities raises considerations about the underlying determinants driving the disparities; and

WHEREAS, It is necessary to promote TNBC education to raise awareness about disease-related disparities and to tackle inequities within health care delivery, such as inadequate access to screening, diagnostic testing, and care to improve early detection and survival; therefore, be it

RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE HUNDRED THIRD GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that we declare the month of March 2023 as Triple-Negative Breast Cancer Awareness Month in the State of Illinois; and be it further

RESOLVED, That we support legislation to reduce Triple-Negative Breast Cancer (TNBC) disparities in early detection and survival by improving education and awareness through health promotion initiatives targeting underserved communities that are disproportionately impacted, which will help in ensuring equitable access and affordability of breast cancer screening, genetic counseling, and diagnostic testing, promoting cultural sensitivity and workforce diversity policies in health care provider training, and guaranteeing timely patient access to clinically appropriate treatment options identified in the National Comprehensive Cancer Network (NCCN) guidelines; and be it further

RESOLVED, That additional legislative provisions should be examined to safeguard affordable, continuous, and equitable patient access to TNBC-related care, services, and medicines along the entire continuum of care.